

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Moxifloxacin Liquid Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

### **1.4 Emergency telephone number**

+1-908-423-6000

# **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

### 2.2 Label elements

# Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

EUH210 Safety data sheet available on request.

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 0,1 - <= 0,2

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.



Version 1.15	Revision Date: 28.09.2024	-	S Number: 32581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017	
If swallowed		:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.		
	mportant symptoms ar known.	nd e	ffects, both acut	e and delayed	
4.3 Indica	tion of any immediate i	med	dical attention an	d special treatment needed	
Treat	ment	:	Treat symptomat	ically and supportively.	
SECTION	15: Firefighting meas	sur	es		
5.1 Exting	uishing media				
Suital	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide ( Dry chemical		
	Unsuitable extinguishing media		None known.		
5.2 Specia	al hazards arising from	the	substance or m	ixture	
-	fic hazards during fire-			bustion products may be a hazard to health.	
Haza ucts	rdous combustion prod-	:	No hazardous co	mbustion products are known	
5.3 Advice	e for firefighters				
	al protective equipment efighters	:		e, wear self-contained breathing apparatus. tective equipment.	
Speci ods	fic extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. aged containers from fire area if it is safe to do	

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment.	
	Follow safe handling advice (see section 7) and personate tective equipment recommendations (see section 8).	al pro-

# 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.



Version 1.15	Revision Date: 28.09.2024	SDS Number: 1732581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017
		Prevent spreadi barriers). Retain and disp	leakage or spillage if safe to do so. ng over a wide area (e.g. by containment or oil ose of contaminated wash water. s should be advised if significant spillages ined.
6.3 Metho	ds and material for c	ontainment and clear	ning up
Metho	ods for cleaning up	For large spills, ment to keep m be pumped, sto Clean up remain bent. Local or nationa posal of this ma employed in the	ert absorbent material. provide dyking or other appropriate contain- aterial from spreading. If dyked material can re recovered material in appropriate container. hing materials from spill with suitable absor- al regulations may apply to releases and dis- terial, as well as those materials and items cleanup of releases. You will need to deter-

mine which regulations are applicable.

certain local or national requirements.

Sections 13 and 15 of this SDS provide information regarding

# 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

#### 7.1 Precautions for safe handling

Technical measures Local/Total ventilation Advice on safe handling	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. Use only with adequate ventilation. Avoid inhalation of vapour or mist. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment
Hygiene measures	:	Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage	:	Keep in properly labelled containers. Store in accordance with
--------------------------	---	----------------------------------------------------------------



Version 1.15	Revision Date: 28.09.2024		DS Number: 732581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017
areas and containers			the particular nat	onal regulations.
Advice on common storage		:	Do not store with Strong oxidizing a Gases	the following product types: agents
•	<b>c end use(s)</b> ic use(s)	:	No data available	

# **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Moxifloxacin HCL	186826-86- 8	TWA	1000 µg/m3 (OEB 1)	Internal

#### 8.2 Exposure controls

#### **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

#### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)

# **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

Physical state : liquid

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

# Moxifloxacin Liquid Formulation

Vers 1.15		Revision Date: 28.09.2024		S Number: 2581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017
	Colour		:	yellow	
	Odour		:	odourless	
	Odour 7	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial be range	oiling point and boiling	:	No data available	
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	No data available	
	Auto-igi	nition temperature	:	No data available	
	Decom	position temperature	:	No data available	
	рН		:	4,1 - 4,6	
	Viscosit Visc	ty osity, kinematic	:	No data available	
	Solubili Wate	ty(ies) er solubility	:	slightly soluble	
	Partition octanol	n coefficient: n- /water	:	No data available	
	Vapour	pressure	:	No data available	
	Relative	e density	:	No data available	
	Density		:	1,0044 g/cm <sup>3</sup> (20	°C)
	Relative	e vapour density	:	No data available	
		characteristics icle size	:	No data available	

### 9.2 Other information

Commission Regulation (EU) 2020/878



# **Moxifloxacin Liquid Formulation**

Version 1.15	Revision Date: 28.09.2024		S Number: 32581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017
Explo	sives	:	Not explosive	
Oxidi	zing properties	:	The substance of	or mixture is not classified as oxidizing.
Evap	Evaporation rate : No data availal		No data availabl	e
Moleo	cular weight	:	No data availabl	e

# **SECTION 10: Stability and reactivity**

#### **10.1 Reactivity**

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### **10.3 Possibility of hazardous reactions**

### 10.4 Conditions to avoid

Conditions to avoid	:	None known.
---------------------	---	-------------

#### 10.5 Incompatible materials

Materials to avoid	: Oxidizing agents
--------------------	--------------------

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Ingestion

Skin contact Eye contact

# Acute toxicity

Not classified based on available information.

### **Components:**

Moxifloxacin HCL:		
Acute oral toxicity	:	LD50 (Rat): 1.320 mg/kg
		LD50 (Mouse): > 435 mg/kg
		LD50 (Monkey): 1.500 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Liquid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

# Skin corrosion/irritation

Not classified based on available information.

# Components:

# Moxifloxacin HCL:

Species	:	Rabbit
Result	:	No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

#### Moxifloxacin HCL:

Species	:	Rabbit
Result	:	Moderate eye irritation

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

### Moxifloxacin HCL:

Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Result: positive
	Test Type: Chromosome aberration test in vitro Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: negative
	Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo :	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Application Route: Oral Result: negative

### Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

# Moxifloxacin Liquid Formulation

Version 1.15	Revision Date: 28.09.2024		DS Number: /32581-00016	Date of last issue: 06.04.2024 Date of first issue: 05.06.2017
-	oductive toxicity			
Not c	lassified based on avail	able	information.	
<u>Com</u>	ponents:			
Moxi	floxacin HCL:			
Effec	ts on fertility	:	Species: Rat Application Rout	500 mg/kg body weight
Effec ment	ts on foetal develop-	:	Species: Monkey Application Rout	
			Species: Rabbit Application Rout Developmental 7	yo-foetal development e: Intravenous injection oxicity: LOAEL: 20 mg/kg body weight etal malformations
Repression Repres	oductive toxicity - As- ment	:	Some evidence animal experime	of adverse effects on development, based on nts.
	<b>T - single exposure</b> classified based on avail	able	information.	
	<b>T - repeated exposure</b> classified based on avail	able	information.	
Com	ponents:			
Moxi	floxacin HCL:			
	et Organs ssment	:	Liver May cause dama exposure.	age to organs through prolonged or repeated

# Repeated dose toxicity

#### Components:

### Moxifloxacin HCL:

Species	:	Rat
LOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	4 Weeks
Species	:	Rat
NOAEL	:	100 mg/kg
Application Route	:	Oral

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Liquid Formulation**

rsion 5	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20241732581-00016Date of first issue: 05.06.2017	
Expos	sure time	: 13 Weeks	
	t Organs	: Liver	
Symp		: Liver disorders	
Speci		: Rat	
NOAE		: 20 mg/kg	
	cation Route	: Oral	
	sure time	: 6 Months	
	t Organs	: Liver	
Symp	toms	: Liver disorders	
Speci		: Monkey	
NOAE		: 50 mg/kg	
	cation Route	: Oral	
	sure time	: 4 Weeks	
Symp	toms	: No adverse effects	
Speci		: Monkey	
NOAE		: 15 mg/kg	
	cation Route	: Oral	
	sure time	: 13 Weeks	
	t Organs	: Gastrointestinal tract	
Symp	toms	: Vomiting	
Speci		: Monkey	
	cation Route	: Oral	
	sure time	: 26 Weeks	
	t Organs	: Liver	
Symp	toms	: Liver disorders	

# 11.2 Information on other hazards

#### Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

# **Components:**

# **Moxifloxacin HCL:**

Ingestion

: Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

# **SECTION 12: Ecological information**

#### 12.1 Toxicity

No data available

### 12.2 Persistence and degradability

No data available

#### 12.3 Bioaccumulative potential

No data available

#### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment

: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

#### 12.6 Endocrine disrupting properties

#### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in
		discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

# **SECTION 14: Transport information**

#### 14.1 UN number or ID number

	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.2	2 UN proper shipping name		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.3	3 Transport hazard class(es)		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.4	4 Packing group		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	IATA (Cargo)	:	Not regulated as a dangerous good
	IATA (Passenger)	:	Not regulated as a dangerous good
14.	5 Environmental hazards		
	Not regulated as a dangerous	aoa	bd

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

# **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		
REACH - List of substances subject to authorisation	:	Not applicable
(Annex XIV)		
Regulation (EC) on substances that deplete the ozone	:	Not applicable
layer		
Regulation (EU) 2019/1021 on persistent organic pollu-	:	Not applicable
tants (recast)		
Regulation (EU) No 649/2012 of the European Parlia-	:	Not applicable
ment and the Council concerning the export and import		
of dangerous chemicals		
Seveso III: Directive 2012/18/EU of the European Parliar	ment	t and of the Council on the control of
major-accident hazards involving dangerous substances		
, Not applicable		

Not applicable

### The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SE	CTION 16: Other information	n	
	Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
	Full text of H-Statements		
	H302	:	Harmful if swallowed.
	H319	:	Causes serious eye irritation.
	H361d	:	Suspected of damaging the unborn child.
	H373	:	May cause damage to organs through prolonged or repeated exposure.
	Full text of other abbreviation	ns	
	Acute Tox.	:	Acute toxicity
	Eye Irrit.	:	Eye irritation
	Repr.	:	Reproductive toxicity
	STOT RE	:	Specific target organ toxicity - repeated exposure



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
1.15	28.09.2024	1732581-00016	Date of first issue: 05.06.2017

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals: OECD - Organization for Economic Co-operation and Development: OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN